Loading...
•
Mar 31, 2022
Mesa Labs Q4 2022 Earnings Report
Mesa Labs reported Q4 2022 and full fiscal year results, showing revenue increase but operating income decrease.
Key Takeaways
Mesa Labs reported a 55% increase in revenues for Q4 2022, reaching $58.879 million, but experienced a 103% decrease in operating income, resulting in a loss of $(110) thousand. Net loss was $(1,784) thousand, or $(0.34) per diluted share. Adjusted operating income increased by 11% to $11.653 million, or $2.22 per diluted share. Organic revenue growth was 12% for the quarter.
Revenues increased by 55% in Q4 2022, with organic revenue growth of 12%.
Operating income decreased by 103% to $(110) thousand due to unusual items.
Net loss was $(1,784) thousand, or $(0.34) per diluted share.
Adjusted operating income increased by 11% to $11.653 million, or $2.22 per diluted share.
Mesa Labs
Mesa Labs
Mesa Labs Revenue by Segment
Revenue by Segment
Sterilization & Disinfection Control Revenue
CapyFin.comBiopharmaceutical Development Revenue
CapyFin.comCalibration Solutions Revenue
CapyFin.comClinical Genomics Revenue
CapyFin.com Forward Guidance
Mesa Labs anticipates a volatile FY23 with lower levels of organic growth due to factors like the war in Europe, pandemic resurgence in Asia, inflation, and rising interest rates.
Positive Outlook
- Company is positioned well for long term growth.
- Company has robust execution.
- Company has improved end market exposure.
- Company has leverage from The Mesa Way operating model.
- Company has solid profitability.
Challenges Ahead
- War in Europe
- Pandemic resurgence in Asia
- Inflation
- Rising interest rates
- Recession risk
Revenue & Expenses
Visualization of income flow from segment revenue to net income